A study on analysis of validity of lateral placental location in prediction of pre eclampsia by Dhivya, N
A STUDY ON ANANLYSIS OF VALIDITY OF
LATERAL PLACENTAL LOCATION IN THE
PREDICTION OF PRE ECLAMPSIA
Dissertation Submitted to
THE TAMIL NADU DR. M. G. R. MEDICAL UNIVERSITY
In partial fulfilment of the regulations
for the award of the degree of
M.D. (BRANCH -II)
OBSTETRICS & GYNAECOLOGY
R.S.R.M. LYING IN HOSPITAL
STANLEY MEDICAL COLLEGE
THE TAMIL NADU DR. M. G. R. MEDICAL UNIVERSITY
CHENNAI, INDIA.
APRIL 2011
CERTIFICATE
This is to certify that the dissertation titled "A  STUDY  ON
ANALYSIS OF VALIDITY OF LATERAL PLACENTAL
LOCATION IN PREDICTION OF PRE ECLAMPSIA" submitted by
Dr.N.Dhivya to the Faculty of Obstetrics and Gynaecology, The
Tamilnadu Dr. M.G.R. Medical university, Chennai in partial fulfillment
of the requirement for the award of M.D. Degree (Obstetrics and
Gynaecology) is a bonafide research work carried out by her
under our direct supervision and guidance
Dr.C.VAMSADHARA, M.D.,Ph.D.,
Dean
Stanley Medical College
Chennai-1
Dr.SHANTHI  DINAKARAN, M.D., D.G.O.
Guide &  Superintendent,
Govt. RSRM Lying in  Hospital,
Stanley Medical College
Chennai -1
Place: Chennai-1
Date :
CONTENTS
S.NO TITLE PAGE NO
ACKNOWLEDGEMENT
1. INTRODUCTION 1
2. REVIEW OF LITERATURE 4
3. AIM OF THE STUDY 31
4. MATERIALS AND METHODS 32
5. RESULTS & ANALYSIS 37
6. DISCUSSION 46
7. SUMMARY 51
8. CONCLUSION 52
9. PROFORMA
10. ABBREVIATION
11. BIBLIOGRAPHY
12. MASTER CHART
ACKNOWLEDGEMENT
ACKNOWLEDGEMENT
I am extremely grateful to Dr.C.Vamsadhara., M.D., Ph.D., Dean,
Govt. Stanley Medical College for granting  me permission to utilize the
facilities of the Institute for my study.
I owe my deep sense of gratitude to Dr.Shanthi Dhinakaran,
M.D., D.G.O., Superintendent, Govt. R.S.R.M Lying in Hospital, who not
only permitted me to do the study but also whose encouragement and
guidance helped me to complete the dissertation.
I express my sincere thanks to Prof. Dr.Hephzibah Kirubamani,
M.D., D.G.O., Ph.D., Prof.Dr.T.Ruckmani, M.D., D.G.O.,
Prof. Bhagyalakshmi, M.D., D.G.O., Dr. Kalaivani, M.D., D.G.O.,  and
Dr. D. Tamil Selvi, M.D.,  Department of Obstetrics and Gynaecology,
R.S.R.M Lying  Hospital for their  guidance and encouragement and
constant support to undertake my study.
I wish to thank all the Assistant Professors and my colleagues who
encouraged me to undertake this study and for their kind support.
I take immense pleasure in acknowledging all the mothers who
gave their consent and co-operated with me in this study.
And most of all I express my gratitude to my family and my
friends who helped me all the way through.
INTRODUCTION
INTRODUCTION
Hypertensive disorders represent the most common medical
complication of pregnancy. It complicates up to 7-10% of pregnancies
of which pre-eclampsia / Eclampsia constitutes 70%, and Chronic
hypertension 30%. Pre-eclampsia has been recognized as pathological
entity since the time of Hippocrates and ancient Greeks.
Pre-eclampsia complicates approximately 5 - 8% of pregnancies
and is a major cause of maternal and perinatal morbidity (SIBAI et al,
1997, 5-8% ACOG 2002).
Pre-eclampsia and Eclampsia contribute 12% of all maternal
deaths in the developing countries (WHO 1999).
It is said that pre-eclampsia, eclampsia contributes to death of a
woman  every  3  minutes  worldwide.  Infants  of  women  with  severe
Pregnancy induced hypertension has 5 fold increase in mortality
compare  to  infants  of  normotensive  women.   Pre-eclampsia  is  a
multiorgan disorder, and usually recognized by new onset of
hypertension and proteinuria appearing in the second half of pregnancy.
2Hypertensive disorders complicating pregnancy represent one
facet of a complex disease process. Gestational hypertension, pre-
eclampsia, eclampsia majority of these conditions are preventable.
This has led to the interest in screening. Screening the deliberate
examination of substantial segments of the population in search for
disease at its earlier stages, is a logical extension of the role of
preventive medicine. If we wish to prevent such disorder we must seek
ways of preventing (or) ameliorating the disease process. In preventing
this disorder the most important factor is lack of timely prediction.
Preeclampsia occurs only in the presence of placenta .
Noninvasive doppler velocimetric studies of the uterine arteries in the
second trimester reveal that abnormal wave forms indicating defective
uterine perfusion is primarily a  consequence of placental implantation
when one uterine artery is the dominant supply of the intervillous flow
.The placenta is located laterally in majority of patients with abnormal
flow velocity waveforms. In the light of these observations, we designed
a prospective study to find out whether the lateral location of placenta as
seen by ultrasound at 18-24 weeks of gestation can be used to predict
the development of preeclampsia.
3For a screening test to be of value, it should be selective, reliably
cheap and easy to perform. It should increase the predictive value and
the prophylactic measures must be effective.
Good antenatal supervision followed by appropriate treatment
will definitely help mother and baby for good outcome.
REVIEW OF LITERATURE
4REVIEW OF LITERATURE
Pregnancy can induce hypertension in normotensive women (or)
aggravate already existing hypertension. Hypertensive disorder in
pregnancy continues to take heavy toll of maternal and fetal lives.
Pre-eclampsia, eclampsia remains a difficult puzzle to solve, and
it is still in a cloud of mystery.
INCIDENCE
Incidence of pre-eclampsia is commonly cited to be about 5%.
Incidence is influenced by parity, race and genetic factors. (Women with
positive family history of pre-eclampsia in her mother or in her sister).
In India the incidence of pre-eclampsia amongst hospital patients
is about 7-10% of all antenatal admission. In United Kingdom, the
incidence is 10%. In USA it is 6-7%. The incidence is found to be
higher among nulliparous women, age less than 20 years and more
than 35 years.
5BLOOD PRESSURE MEASUREMENTS
1. Conventional mercury sphygmomanometer - Gold standard for
blood pressure measurement.
2. Use of bell of stethescope as it better amplifies the Korotkoff (K)
Sound.
3.        Cuff size should be adequate. Bladder length 80% of arm
circumference,     and    width     should     be    40%    of    arm
circumference.
4.  Patient should be in sitting posture with her right arm well
supported in a horizontal position at the level of heart and her feet
supported (Sibbai).
5.     Inflate  the  cuff  above  the  systolic  pressure  as  recognized  by
disappearance of the radial pulse.
6.     Use  of  Korotkoff  (V)  (disappearance  of  sound)  to  determine
diastolic blood pressure.
6CLASSIFICATION
NATIONAL HIGH BLOOD PRESSURE EDUCATION
PROGRAMME WORKING GROUP (2000) (NHBPEP)
I. Gestational Hypertension
Gestational Hypertension or transient Hypertension, Previously
called as Pregnancy Induced Hypertension.
? 140/90 mmHg of BP for the first time in pregnancy
? No proteinuria
? Blood pressure returns to normal < 12 weeks postpartum
? Final diagnosis made only postpartum
II. Pre Eclampsia
Occurrence of Hypertension in combination with proteinuria
developing after 20 weeks of gestation in a previously normotensive,
non proteinuric pregnant women.
It is a pregnancy specific syndrome of reduced organ perfusion
secondary to vasospasm and endothelial activation.
7Minimum criteria Increased certainity of Pre eclampsia
? ? 140/90 mm Hg>20 weeks
of gestation
? Blood Pressure ? = 160/1l0 mmHg
? Proteinuria ? = 300mg/24 hrs
(or) ? = 1 + dipstick
? Proteinuria 2g/24 hours (or) ?=2+
dipstick
? Serum Creatinine 1.2mg/dl unless
known to be previously elevated
? Platelets < l,00,000/mm3
? Microangiopathic haemolysis
? Elevated ALT/AST
? Persistent headache/Other cerebral
or visual disturbances
? Persistent epigastric pain.
III.      Eclampsia
Seizure that cannot be attributed to other cause in a women with
pre-eclampsia.
IV. Superimposed Pre-eciampsia on Chronic Hypertension
New onset proteinuria > 300 mg/24 hours in hypertensive women
but proteinuria before 20 weeks of gestation.
V. Chronic Hypertension
BP ? 140/90 mmHg before pregnancy or diagnosed before 20
weeks gestation not attributable to gestational trophoblastic disease.
8Proteinuria
It is directly proportional to maternal and perinatal mortality,
(Harth et al 2000) and morbidity.
It is an important sign of pre eclampsia (Chesley 1985). It reflects
the glomerular damage that causes leakage of proteins through the
basement membrane.
Significant proteinuria is defined by 300mg/24 hours or persistent
30mg/dl (1+dipstick) in random clean catch sample on at least 2
occasions collected 6 hours apart. If proteinuria is >5gm/24 hours (or)
persistent 3+ dip stick (or) more the condition is called as severe pre
eclampsia (ACOG Practice Bulletin No.33s January 2002).
Edema
Edema is no longer a part of current definition (or) as a diagnostic
criteria of pre- eclampsia (Williams 22nd Edition) and it is seen in
nearly 80% of women in last few weeks (Robetson 1971).
Weight Gain
Excessive weight gain of >0.5kg/week because of extracellular
fluid volume expansion).
9THEORIES REGARDING CAUSATION OF PRE-
ECLAMPSIA
IMMUNOLOGICAL
The trophoblastic cells do not express the usual class-I & II MHC
antigen, they express unique HLA-G enclosed class-I MHC molecule
which allow the trophoblast cells to invade deep into spiral arteries. In
patients developing pre-eclampsia there is immune resistance to the
invading trophoblast by the maternal immune system, results in poor
spiral artery remodeling which is a initially cited feature in pre-
eclampsia (ZHOU 1977). Pre-eclampsia is immune mediated, certainly
the microscopic changes at maternal placental interface are suggestive
of acute graft rejection (Labarrere 1998).
The risk is enhanced when formation of blocking antibodies to
antigenic sites in placenta is impaired (Bardegue and Asso, 1991) (or)
where the number of antigenic sites is increased as in hyperplacentosis
(Beer 1979).
?  T helper cells were in a lower proportion in pre-eclampsia
(Bardeguez and Associates). T-lympohcyte secrete cytokines that
promote implantation and their dysfunction may favour pre-
eclampsia (Hayashi & Associates 2004, Whitecar & Collegues
2001).
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? Antibodies to B2 glycoprotein I is more relevant immune
complex and antiendothelial antibodies may be involved (Taylor
etal, 1999).
? Immunocytochemical analysis - VCAM, increased in Pre-
eclampsia.
? The pre-eclampsia develops more frequently in multiparous
women impregnated by a new Consort (Mostello & Conera 2002,
Trapin and Colleagues 1996).
GENETIC SUSCEPTIBILITY
Hereditary estimate of 31% of pre-eclampsia (Nilsson et al)
1. Chesley and Cooper 1986, Pregnancy Induced
Hypertension
is inheritable both by single gene (Broughton Piplus 1999)
and Multifactorial inheritance.
2 Modes
a) Simple recessive model with genes acting in the mother
(gene on chromosome 1, 3, 9)
b) Dominant model with incomplete penetration
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2. Kilpatric reported an association HLA DR4 the
transmission  from  mother to   daughter  is  through
HLADR4
3. Angiotensinogen gene variant T235 - high incidence of
PIH (Arngrimsson et al)
4. Dizon Townsend and colleagues found high incidence of
factor V laden mutation polymorphism gene variant 202109
5. Epigenetic features (or) imprinting is also involved in the
pathogenesis of pre-eclampsia susceptibility locus on
chromosome lOq 22-1. (Dudejans et al).
6. Hyperhomocystinaemia associated with methyltetrahy-
drofolate (6778) Homozygozity (Coffer et al).
7. Polymorphism of TNF a and Gene - Mediating endothelial
dysfunction, Lymphotoxins, ILi.
8. The eNOS gene susceptibility occurs in the region of
chromosome  7q 36.
PLACENTA AND PRE ECLAMPSIA
Many investigators believe that the placenta is the trigger for endothelial cell
injury.  Evidence suggests that hypoperfused placentas produce various factors that
are capable of injuring endothelial cells. Recent data suggest that circulating
factors that interfere with the action of vascular endothelial growth factor (VEGF)
and placental growth factor (PlGF) play a major role in maternal manifestation of
the disorder.
 Placental hypoperfusion or ischemia in preeclampsia has many causes.
Preexisting vascular disorders such as hypertension and connective tissue disorders
can result in poor placental circulation. In cases of multiple gestation or increased
placental mass, it is not surprising for the placenta to become underperfused.
However, most women who develop preeclampsia are healthy and do not have
underlying medical conditions. In this group of women, abnormally shallow
placentation has been shown to be responsible for placental hypoperfusion.
          The shallow placentation noted in preeclampsia is a result of the inability
of trophoblasts to invade the decidual vessels. In normal pregnancies, a subset of
cytotrophoblasts called invasive cytotrophoblasts migrate through the implantation
site and invade
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decidua tunica media of maternal spiral arteries and replace its
endothelium in a process called pseudovascularization. As  a  result  of
these changes, these vessels undergo transformation from small
muscular arterioles to large capacitance, low-resistance vessels. This
allows increased blood flow to the maternal-fetal interface. Remodeling
of these arterioles probably begins in the first trimester and ends by
18-20 weeks' gestation. However, the exact gestational age at which the
invasion stops is unknown.
In preeclampsia, this invasion of the decidual arterioles is
incomplete. The  invasive  cytotrophoblasts  fail to replace tunica media,
resulting  in  mostly intact arterioles that are capable of vasoconstriction.
Histologic evaluation of the placental bed demonstrates few
cytotrophoblasts beyond the decidual layer.
The trophoblast differentiation along the invasive pathway
involves alteration in the expression of a number of different classes of
molecules, including cytokines, adhesion molecules, extracellular
matrix, metalloproteinases, and the class Ib major histocompatibility
complex molecule, HLA-G Angiogenesis is critical for successful
placentation. Both VEGF and PlGF promote angiogenesis by interacting
with the VEGF receptor family.
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While both growth factors are produced by placenta, the serum
level of PlGF rises much more significantly in pregnancy. Taylor et al
demonstrated that the serum level of PlGF decreased in women who
later developed preeclampsia. The fall in serum level was notable as
early as the second trimester in women who developed preeclampsia and
intrauterine growth restriction.
 In 2003, Maynard et al observed that  the serum levels of
both  VEGF  and  PlGF  were  decreased  in  women  with
preeclampsia. However, the magnitude of decrease was less pronounced
for VEGF since its serum level was not as high as PlGF, even in normal
pregnancy. Others have confirmed this finding and showed that the
serum level of PlGF decreased in women before they developed
preeclampsia.
Khong et al showed that poor trophoblastic conversion of spiral
arterioles leads to development of pre eclampsia. Both uterine arteries
have a significant number of branches. When placenta is laterally
located the uterine artery close to the placenta has lower resistance than
the one opposite from it.  In patients with centrally located placentas
both uterine arteries demonstrate similar resistance.
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It is possible that when the placenta is centrally located, the
uteroplacental blood flow needs are met by equal contribution from both
the uterine arteries. However when the placenta is laterally located., in
the majority of patients the uteroplacental blood flow needs are to be
met primarily by one of  the uterine arteries,  with some contribution by
the other side via collaterals. This collateral contribution may  be
deficient in some individuals facilitating development of pre eclampsia.
ENDOTHELIAL DYSFUNCTION
Endothelial damage account for all aspects of pathophysiology of
pre-eclampsia (Roberts et al 1998).
Endothelial dysfunction results from "Generalised perturbation of
normal maternal intravascular inflammatory adaptation to pregnancy
(Redman and Colleagues (1999).
Immunologically mediated deficiency in trophoblastic invasion of
spiral arteries results in release of a number of factors into maternal
circulation. These changes inturn provoke activation of vascular
endothelium (Hayman and Asso., 2000, Ness and Roberts 2000, Walker
2000). Damaged endothelium activates endothelial cells to promote
coagulation and increases sensitivity to vasopressor agents.
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Reduction of unbound serum level of Angiogenic factors such as
VEGF and PLGF due to upregulation of soluble fms like tyrosine kinase
receptor  (Maynard  et  al)  and  Serum  level  of  sFltl  is  increased  in  pre-
eclampsia leads to endothelial dysfmction.
Prostaglandin theory (Wang et al 1991): In pre-eclampsia, the
balance is between PGI2 & TXA2 (Prostocycline) (Thromboxane A2)
is titled so TXA2 is found to increased (Walsh 1985).
ENDOTHELINS
They are polypeptides with potent vasoconstricting property,
higher level of Endothelin I is found in pre-eclampsia
(Clark Schiffl992).
NITRIC OXIDE
Decreased in pre-eclampsia (Anumba Ford Ant obsgyn 181:
14 (1999). This concept is disproved. Decreased endothelial nitric oxide
synthase expression (Wang & Collagen 2004). Increased production
of Nitricoxide as a compensatory mechanism (Benedetto & Asso.,
2000). It is a consequence of hypertension, but not the cause
(Morris and Colleagues 1996).
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Ionic calcium is crucial for synthesis of vasosubstances in the
endothelium like PGI2 and Nitricoxide. An alteration in the action of
Nitricoxide may be related to inactivation by free radical superoxide
(secondary to inflammatory process) (Lopez et al).
OXIDANTS AND ANTIOXIDANTS
A work by Hubal et al have confirmed that pre-eclampsia may
have its origin in a disturbed oxidation mechanism. Increased free
radical in Pre-eclampsia (Wisdom and Ass., 1991), free radical causes
endothelial damage.
PLACENTAL PROTEINS
Corticotrophin releasing factor, HCG, Activin A & inhibin A are
said to play a role in pathogenesis of Pregnancy induced hypertension.
VASOSPASM
Vasospasm that characteristic of the disease (Volhard). Vasopasm
causes endothelial damage and interendothelial cell leakage which
results in subendothelial deposition of fibrin and platelets and hence
uteroplacental insufficiency (Brunner & Gavras 1975).
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SCREENING TEST
Comparison of various other screening tests with urinary calcium/
Creatinine ratio as a predictor of Pre-eclampsia.
A variety of biochemical and biophysical markers based primarily
on rationales implicated in the pathology and pathophysiology of
pre-eclampsia have been proposed for its prediction.
The good screening test should be sensitive, cheap, easy to
perform, and readily interpretable with high predictive value.
Screening test can be divided into 3 categories.
I.        Haemodynamic Tests
1. Angiotension II infusion test: Talledo et al 1968
Abnormal vascular reactivity of patients destined to develop pre-
eclampsia may be detected several weeks before the clinical signs and
symptoms appears. Women requiring less than 8ng/kg/minute of
Angiotension II to raise their diastolic BP by 20mmHg had a positive
predictive value of 20-40% of developing pre-eclampsia (Friedman).
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2. Isometric hand Grip Test
Dagani et al Increase in diastolic pressure of more than 20mmHg
during a hand grip exercise test at 28-32 weeks had positive predictive
value of 20-30%. This test is not affected by positional change and is
safe  and   easily  performed,   although   it   is   time   consuming   taking
upto 30minutes to perform. Since hand grip represent sympathetic
nervous system activity. There is little evidence that pre-eclampsia is
mediated by sympathetic activity. This requires further evaluation.
False negative 4% & False positive 19%.
3. Roll over test
Proposed by Gant et al, An increase > 20mmHg of diastolic blood
pressure induced by having women assume the supine position after
lying left lateral position done at 28 - 32 weeks was shown to be
associated with later on occurrence of pre-eclampsia is 33%. Though the
test, is simple to perform and requires only time and personnel rather an
elaborate equipment.
4. Mean arterial pressure - Page and Christianson
Suggested that patients with MAP of >90mmHg in II trimester
should be regarded as a risk category but the predictive value varies
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greater  from  one  study  to  another.  The  position  of  the  arm  relative  to
heart level also affect the recording. There is also variation of blood
pressure with the circadian rhythm, values being highest during the
afternoon and early evening. This method to be effective, increased
uniformity of recording measurement is necessary.
5. Uterine artery Doppler Velocimetry
Doppler measurement of uterine artery impedance in the mid II
trimester (18-24 weeks) is an early screening test (Bewley, 1991),
Chappel based on the presumption that impaired trophoblastic invasion
of spiral arteries causes decreased utero placental blood flow. The
presence of  a high systolic - diastolic ratio, persistence of diastolic
notch may predict pre-eclampsia (Irion et al 1998) and Resistance
Index > 0.58. Positive predictive value was only 28% (Friedman and
Lindheimer 1999). Studies concluded that the test was not helpful in the
management of  individual patients.
6. Placental  Position
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URINARY ASSAYS
1.       Urinary calcium excretion
Studies found that urine calcium excretion is reduced in pre-
eclampsia. A study showed that urinary calcium excretion average of
313+140mg in normal pregnancy and 248+134 in transient
hypertension. Hypocalciuria is due to increased distal tubular
reabsorption alternatively proximal tubular reabsorption. 24 hour urinary
calcium excretion less than 12 mg/ dl had sensitivity of 88% and
positive  predictive  value  of  91%.  (Sanchez  -  Romos,  Obstet  &
Gynecol 1991).
Another study reported that patient with pre-eclampsia had
significantly less excretion of total calcium (129.7 + 18.7mg/24 hours)
than normotensive (283.9 + 12.3) or those with gestational hypertension
(233.2 + 22.3) (P = 0.0001) using a receiver operator curve, urinary
calcium threshold of 12mg/ dl was choosen as a predictor for the
development of pre-eclampsia with sensitivity of 83% specificity of
91%, Positive predictive value 83, Negative predictive value 91.
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2.        Urinary calcium / Creatinine Ratio
A  number  of  studies  have  shown  that  a  low  calcium  and
creatinine excretion is a valuable marker for pre-eclampsia prediction.
Since creatinine clearance is not significantly different among
normotensive and pre-eclampsia, (134.4 + 14.9) in Pre-eclampsia (141.9
+ 7.2) and in gestational Hypertension, (150.2+6.5) in normotensive
pregnant women. Studies were done using single voided urinary calcium
/ creatinine ratio in the prediction of pre-eclampsia and it correlated well
with 24 hours calcium excretion. Hence 24 hours urinary calcium
excretion can be estimated from single voided urine sample.
3. Micro albuminuria
By Radio immuno assay can detect microalbuminuria of the value
>11 ug/ml when done between 24-34 weeks it indicates positive result.
4. Urine Kallikrein / Creatinine ratio
Kallikrein Creatinine ratio of <170 between 16 and 20weeks of
pregnancy predicts future development of pre-eclampsia. Camphell et
al., 1987: sensitivity of 83% false positive ratio of 50%, false negative
ratio 10%, positive predictive value of 91%.
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5. Urinary metabolites of PGI2 - help in diagnosis of pre-eclampsia
6. Markers for endothelial dysfunction.
Fibronectin, a glycoprotein synthesized in the vascular
endothelium elevated in pre-eclampsia - 2 fold increase in fibronectin,
>400 ug/ml. Positive predictive value was only 39% negative predictive
value 98% (Chavarria et al, 2003) Sensitivity is quiet low only (69%)
(Pallberg & Colleagues).
Plasminogen inhibitor 1 is increased relative to plasminogen
activator (Caron and Colleagues 1991) Thrombomodulins, cell adhesion
molecules and Endotheline I are also found to be increased.
7. Coagulation factors
1) Increased Thromboxane A2 (Fitzgerald et al). 2) Increased
Factor VIII. 3) Decreased Antithrombm III. 4) Thrombocytopaenia and
abnormalities platelet function (Aggregation).
8. Cytokines
Increase IL and TNF a - not yet proved sufficiently (Savvidon and
colleagues 2002, Benyo 2000).
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9. Anti angiogenic factor
Levin RJ et al, soluble fms like Tyrosine Kinase I, Endoglin-
Increased, Ratio of sFltl: PIGF - more accurate (Devivo et al).
MARKERS OF OXIDATIVE STRESS
1. Malondialdehyde lipid peroxidation (Hubel & Co-authors 1989).
2. Pro oxidants (Herbert and Colleagues 1994)
3. Homocysteine (Cotter and Associates 2001) elevated level around
mid pregnancy had a 3-4 fold risk of development of pre-
eclampsia.
4. Triglycerides, free fattyacids and lipoprotein (Hobel and
Colleagues 1996).
5. Prostaglandin Isomerase; marker of impending pre-eclampsia
(Regan and Fitz Gerald, 1997).
These tests are not economical they are not popularized.
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OTHERS
1. Uric Acid
Elevated uric acid levels exceeding 5.9 mg/dl is considered
significant correlation well with sensitivity and perinatal outcome.
2. Fibronectin
Increased serum cellular fibronectin level in some women with
pre-eclampsia (Magann EF et al).
3. Placental peptides
HCG (Ashoc R & colleagues 1997) inhibin A & inhibin B - in the
search for early pregnancy marker for pre-eclampsia (Woodruff)
4. Plasma P Selectin
Plama P selectin as the earliest predictor in the first trimester is
under study.
5. Urinary podocyte excretion
Highly sensitive and specific marker (Garovic et al).
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6. Enzymes and Hormones:
Increased levels of plasma cystyl amino peptidase, Pappa-A
(Wood and Durham) and high level of (3 HCG (Noguera et al).
7. Foetal DNA
Foetal DNA in maternal serum may be predictive of pre
eclampsia.
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PREVENTION OF PRE-ECLAMPSIA
Pregnancy is a process of physiologic adaptation which occur
primarily is an effort to supply the developing fetus with their nutrients
that are essential for its proper development and growth.
Preventive measures have been concentrated to relieve vasospasm
and to correct the disturbed prostaglandin synthesis which lead to
platelet aggregation and endothelial damage. There are no definite
preventive methods but attempt should be made for early detection of
high risk patients.
Thomas Brewer rightly stated that pre-eclampsia is a
complication of maternal malnutrition whose symptoms can be largely
eliminated by eating a well balanced diet.
A study by the Dietary Approaches to stop Hypertension (Dash)
demonstrated that dietary manipulation significantly lowers the Blood
pressure.
Prevention can dealt with
1. Non medical measures
2. Medical measures.
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SALT RESTRICTION
This may be used as a means to prevent the onset of essential
hypertension but not be used for gestational Hypertension and
Pre-eclampsia.
BED REST
This may be useful in known hypertensive patients to reduce the
severity.
FISH OIL
The benefit from fish oils seems to be associated with long chain
n-3 fatty acids, C-20, n3 eicosepentoicacid and docosepentanoicacid &
docosahexanoid acids. They decrease platelet aggregation on endothelial
cells and leads a relative state of vasodilatation.
PLANT OIL
Linoleic  and  Evening  primrose  oil  (3mg  Linoleic  +  32mg  of
Gammalinoleic acid / day.
CALCIUM
Proposed mechanism where by calcium supplementation may
reduce blood pressure.
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Reduced serum calcium
Increases Vit. D stimulation - interact with renin / angisotensin
(Through its link to PTH) Vit. D receptors present in the smooth muscle
reduction of altered Vit. D metabolism smooth muscle proliferation
Development of atherosclerosis
Hypertension
High intake of calcium of L.3g/d showed a reduced incidence of
both Pre-eclampsia & Eclampsia (Villar, J American J Clin -Nutrition
1980). World Health Organization (2006) supplementation with
calcium 1.5g/day significantly reduces the risk of maternal neonatal
morbidity and preterm delivery in the later among young women.
Cochrane systematic review noted protective effects of calcium
supplementation only in women with low calcium intake.
ANTIOXIDANT
Antioxidant   therapy   significantly   reduced   endothelial   cell
activation in a study performed by (Chappell and associates, Lancet
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1999). There was a significant reduction in the incidence of Pre-
eclampsia in women who was given with vitamin C and E.
MEDICAL MEASURES
Low dose aspirin appears to be beneficial for women at high risk
of pre-eclampsia (Cochrane Review - 19% reduction in risk of pre-
eclampsia).
AIM OF THE STUDY
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AIM OF THE STUDY
To analyse  whether placental location as determined by
ultrasound at 18-24 weeks can predict the subsequent development
of  pre-eclampsia.
MATERIALS AND
METHODS
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MATERIALS AND METHODS
This   study  was   conducted   at  department  of Obstetrics  and
Gynaecology, Govt. R.S.R.M. Lying in Hospital attached to  Stanley
Medical College, Royapuram, Chennai.
STUDY PERIOD:  The Period of Study was from July 2009 to
August  2010.
STUDY DESIGN: PROSPECTIVE STUDY
300 Pregnant women attending the antenatal clinic at R.S.R.M.
Lying in Hospital, were registered in this study. Only those pregnant
women whom we could follow to term and were planning delivery at
R.S.R.M. Lying in Hospital, Royapuram Chennai, were included in this
study.
The location of the placenta was determined by ultrasound at
18-24 weeks in all the 300 women. The placenta was classified as
central when it was equally distributed  between the right and the left
side of the uterus irrespective of anterior, posterior or fundal position.
When 75% or more of the placental mass was to one side of the
midline, it was classfied as unilateral right or left placenta. BP was
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measured in every subsequent visit. The end point of the study was the
development of hypertension as per  the ACOG criteria or delivery.
PATIENTS SELECTION CRITERIA
Inclusion Criteria
1.      Gestational age between 18-24 weeks.
2.   Women who intend to have their deliveries at RSRM lying in
hospital.
Exclusion Criteria
1. History chronic hypertension
2. History of Diabetes Mellitus
3. History of Renal disease
4. Blood pressure > 140/90 mm Hg
5. Evidence of proteinuria by the dipstick method.
The study was done on asymptomatic primi, and pregnant women
with Rh Negative, with previous h/o pre-eclampsia, family h/o pre-
eclampsia were also included.
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METHODOLOGY
In all the pregnant women included in the study, a written
informed consent was obtained.
1. No dietary alterations were recommended
2. Detailed history was taken.
3. Complete examination
i. General examination
ii. Clinical examination
- Cardiovascular system
- Respiratory system
- Central nervous system
iii.  Obstetric examination was done.
4. Blood Pressure
i.  In sitting posture
ii.  Phase  Korotkoff   V  sound  was  taken  to  determine  the
diastolic component
5. Basic Investigations
i.  Haemoglobin
ii. Blood Grouping and Rh Typing
iii. Urine-Albumin
- Sugar
- Deposit
6.  The location of the placenta was determined by ultrasound at 18-24
weeks in all the 300 women. The placenta was classified as central when it was
equally distributed between the right and the left side of the uterus irrespective of
anterior, posterior or fundal position.
When 75% or more  of the placental mass was to one side of the midline, it
was classified as unilateral right or left placenta. The end point of the study was the
development of hypertension as per the ACOG criteria or delivery.
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7. Followed up with routine antenatal visits for signs and
symptoms of pre-eclampsia by routine examination of blood pressure,
serial weight, edema, and investigation of pre-eclampsia when required
and results were tabulated.
8. Mode of delivery and fetal outcome was noted
RESULTS
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RESULTS
TABLE-I
DISTRIBUTION OF PERSONS IN STUDY GROUP
ACCORDING TO AGE
<20 yrs 20-25 yrs 25-30yrs >30 yrs
63 152 63 22
21% 50.7% 21% 7.3%
50.7% of mothers were in the 20-25 years age group. 21% in
<20 years age group. Another 21% in 25-30 years age group. 7.3% in
the greater than 30 years age group.
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TABLE-II
DISTRIBUTION OF PATIENTS WITH PRE-ECLAMPSIA ACCORDING
TO AGE
<20 years 20-25 years 25-30years >30years
4 26 8 4
The relationship of maternal age and incidence of pre-eclampsia shows
higher incidence among young primi gravida and markedly increased incidence
among older primigravida. In study group preedampsia was high between 20-25
years and pre-eclampsia was high above 30 years.
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TABLE-III
DISTRIBUTION OF PATIENTS WITH PRE-ECLAMPSIA
ACCORDING TO PARITY
PARITY TOTAL
PRE-ECLAMPSIA
POSITIVE
%
Primigravida 222 34 81%
Multigravida 78                    8 19%
"Above  table  shows  the  distribution  of  patients  with  pre-
eclampsia according to parity. Pre eclampsia is more common in
primigravida. This table show high incidence of pre-eclampsia in
primigravida (81%) than in multigravida.
Distribution of Patients with pre-eclampsia according to
parity
Primi
81%
Multi
19%
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TABLE-IV
RELATIONSHIP OF PLACENTAL POSITION AND
DEVELOPMENT OF PRE-ECLAMPSIA
PLACENTAL
POSITION
DEVELOPED PRE
ECLAMPSIA
NORMOTENSIVE
CENTRAL (228) 8(19.1%) 220(85.2%)
LATERAL(72) 34(80.9%) 38(14.8%)
This  table  shows  the  relationship  of  placental  position  and
development of pre-eclampsia. 34 patients in the lateral placenta group
developed pre eclampsia which accounted to 81% of all pre eclamptics.
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TABLE-V
RELATIONSHIP OF PLACENTAL POSITION AND
DEVELOPMENT OF PRE-ECLAMPSIA IN HIGH RISK
WOMEN
PLACENTAL
POSITION
DEVELOPED PRE
ECLAMPSIA
NORMOTENSIVE
CENTRAL (53) 5(33.3%) 48(88.9%)
LATERAL(16) 10(66.7%) 6(11%)
 This  table  shows  the  relationship  of  placental  position  and
development of pre-eclampsia in the high risk group. 10 patients in the
lateral placenta group developed pre eclampsia which accounted to
66.7% of all pre eclamptics in the high risk group.
p Value is 0.001 and is highly significant.
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TABLE-VI
RELATIONSHIP OF PLACENTAL POSITION AND
DEVELOPMENT OF PRE-ECLAMPSIA IN LOW RISK
WOMEN
PLACENTAL
POSITION
DEVELOPED PRE
ECLAMPSIA
NORMOTENSIVE
CENTRAL (175) 12(44.4%) 163(79.9%)
LATERAL(56) 15(55.6%) 41(20.1%)
This  table  shows  the  relationship  of  placental  position  and
development of pre-eclampsia in the low risk group. 56% of the pre
eclampsia patients in this group had lateral placenta.
 Central Placenta Lateral Placenta
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TABLE-VII
DISTRIBUTION OF PATIENT ACCORDING TO THEIR FIRST
APPEARANCE OF PRE ECLAMPSIA IN WEEKS
Gestational age in weeks Number of Patients
26-28 1
29-31 3
32-34 6
35-37 15
38-40 17
>40 -
The above table shows most patients developed pre-eclampsia
between gestational age of 36 to 40 weeks indicating that the incidence
is higher in later part of gestation
Distribution of Patients according to their first
apperance of pre eclampsia in weeks
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TABLE-VIII
DISTRIBUTION OF PATIENTS ACCORDING TO SEVERITY
OF PRE-ECLAMPSIA IN STUDY AND CONTROL GROUP
Type of pre-eclampsia Study group
Mild Pre-eclampsia 38
Severe Pre-eclampsia   4
42
The above table denotes that distribution of persons in study
group according to severity of pre-eclampsia. 38 patients shad mild pre-
eclampsia and 4 patients in the study group had severe pre-eclampsia.
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TABLE-IX
PREDICTIVE VALUE OF PLACENTAL POSITION IN
PREDICTING PRE ECLAMPSIA
PLACENTAL
POSITION
DEVELOPED PRE
ECLAMPSIA
NORMOTENSIVE
CENTRAL (228) 8(19.1%) 220(85.2%)
LATERAL(72) 34(80.9%) 38(14.8%)
This screening test has
? Sensitivity of 81%
? Specificity of 85.3%
? Positive predictive value of 47.2%
? Negative predictive value of 96.4%
? p value < 0.001 which is significant.
DISCUSSION
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DISCUSSION
The study was conducted on asymptomatic pregnant women
between 18-24 weeks of gestation. All women included in the study
were normotensive with a BP lessthan 140/90 mmHg.
Placental location was determined by realtime ultrasonogram.
Placenta was classified as right or left lateral regardless of its antero
posterior position. For purpose of analysis the patients with right or left
placentas were classified as having unilaterally located placentas.
In this study 300 patients were registered. Out of which 231 were
in the low risk pregnancy group and 69 in the high risk pregnancy
group.  Of the 300 patients 42 developed pre eclampsia with incidence
of 14%.
INCIDENCE
Mudaliar & Menon 10%
Sanchez Ramos 14%
Ritu Kamara et al 13.6%
Rodriguesz et al 10.6%
Present study 14%
Present study shows 14% incidence of pre eclampsia which is
similar  to Sanchez Ramos study.
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AGE INCIDENCE
Women of different age group were included in the study and
control group. 50.7% of those who developed pre-eclampsia were in the
age group of between 20-25 years. This is accordance with
MACGILLVIRAY'S report on age incidence of Pre-eclampsia which
states that the incidence of pre-eclampsia is high among young
primigravida. 7.3% of those who developed pre-eclampsia were in the
age group more than 30 yrs. Observation showed that the extremes of
age group has predilection for pre-eclampsia.
PARITY
The incidence of pre-eclampsia is high in primigravida  when
compared to multigravida .The overall incidence of pre-eclampsia in this
study was 14% The overall incidence of pre-eclampsia inprimigravidae
in this study was 15%.
The incidence of pre-eclampsia in primigravida quoted in
different studies.
Long & Oats 14.1%
Norwitz et al., 11.9%
Williams 7.6%
Present study 14%
Our study showed results similar to the study by Long and Oats.
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                Of the 300 patients enrolled 231 were in the low risk
pregnancy group. Totally 42 women developed pre eclampsia- incidence
of 14%. In all 228 women had central placenta and 72 women had
lateral placenta. Only 19% (8 women ) with central placenta developed
pre eclampsia. But in the lateral placenta group 80.9% developed pre
eclampsia of  which 4 had severe pre eclampsia.  1 woman in this  study
developed eclampsia nbecause of poor compliance.
        In high risk group, 69 women-
? 14 patients had GDM,
? 13 patients- BOH,
? 3-treated for infertility and
? 42 patients had medical disorders like Bronchial Asthma,
Epilepsy, heart diseases, anaemia, hematological disorders,
thyroid dysfunction and Rh negative.
Of these 53 women had central placenta and 16 women had
lateral placenta. In the lateral placenta group 67% developed pre
eclampsia.
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In low risk group with 231 women, 175 had central placenta and
56 had lateral placenta. In the lateral placenta group 56% developed pre
eclampsia.
My study has a sensitivity of 81% in predicting pre eclampsia,
and specificity of 85.3%. The positive predictive value of this screening
test is 47.2% and so it is for various other screening tests.
Comparison of predictive value of placental laterality in present
study with other studies
Author Year
No of
patients
Sensitivity
in%
Specificity
in %
PPV
in %
NPV
in %
Muralidahar Pai
et al
2005 426 73 86 51 94
Alexander
Kofinas  etal
1989 153 79 81 46 90
Ozcan et al 1996 182 72 80 52 94
Present Study 2010 300 81 85.% 47.2% 96.4
COMPARISON OF OUR STUDY WITH OTHER STUDY
Our study shows a sensitivity of 81% correlating with Kofinas et al study.
Our specificity of  85.3% correlated well with Muralidhar Pai’s study.
         Our positive predictive value of 47.2% correlated with Kofinas et al study
and negative predictive value of 96.4% correlated well with Muralidhar Pai and
Ozcan et al studies. Thus placental position is an easy non invasive test to predict
pre eclampsia.
SUMMARY
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SUMMARY
The results of analysis of the study is summed up as follows:
1. Pre-eclampsia developed in 14% of patient population between
36-40 weeks of gestation mostly. Patients developed pre-
eclampsia in the form of raised blood pressure, proteinuria and
with or without odema.
2. Nulliparity was found to be a significant high risk factor.
3. 47% patients in the lateral placenta group developed pre
eclampsia. Only 3.5% in the central group developed pre
eclampsia.
4.  80.9% of the pre eclampsia patients had lateral placenta and only
19.1% had central placenta.
5. Sensitivity – 81%, specificity – 85.3% , positive predictive value
-  47.2%, and negative predictive value of 96.4% which is
significant.
CONCLUSION
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CONCLUSION
The  study  shows  that  placental  position  determined  by
ultrasonogram  between 18-24  weeks of gestation is an excellent
screening tool for the prediction of pre-eclampsia among numerous
screening test with specificity of 85.3% and sensitivity of 81% and
positive predictive value 47.2%, and negative predictive value 96.4%.
This test is ideal because
• Simple and easy to perform
• Inexpensive  and part of the anomalies scan performed.
•  Non invasive and convenient for the patient
        Lateral placentation helps identify the population who is at greatest
risk to be included in primary preventation program.
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133.
134.
26
24
23
19
22
26
23
24
27
18
21
35
16
20
29
18
21
28
24
30
18
22
21
30
19
23
24
34
24
30
17
24
29
25
18
18
25
29
30
23
17
24
29
16
23
28
18
22
27
24
23
33
24
23
24
18
21
26
23
24
17
20
28
23
19
21
27
24
18
PRIMI
PRIMI
PRIMI
PRIMI
G2P1L1
G2P1L1
PRIMI
PRIMI
G2P1L1
PRIMI
PRIMI
PRIMI
PRIMI
PRIMI
G3P2L2
PRIMI
PRIMI
G2P1L1
PRIMI
G2P1L1
PRIMI
G3P2L2
PRIMI
G2P1L1
PRIMI
PRIMI
PRIMI
PRIMI
PRIMI
G2P1L0
PRIMI
PRIMI
PRIMI
PRIMI
PRIMI
PRIMI
G2P1L0
PRIMI
G2P1L1
PRIMI
PRIMI
G2P1L1
PRIMI
PRIMI
G2P1L1
PRIMI
PRIMI
G3P2L1A1
G2P1L1
PRIMI
PRIMI
PRIMI
G2P1L1
G2P1L1
G2P1L1
PRIMI
PRIMI
PRIMI
G3P1L1A1
G2P1L1
PRIMI
PRIMI
PRIMI
PRIMI
PRIMI
PRIMI
G2P1L1
PRIMI
PRIMI
120/70
120/80
110/80
120/80
120/80
100/80
120/70
120/80
120/80
120/80
120/80
120/80
110/60
120/80
120/80
120/80
120/80
120/80
120/80
120/80
100/60
120/80
120/80
120/80
120/80
120/80
110/80
120/70
120/80
120/80
120/80
110/80
120/70
120/80
110/60
120/80
110/70
120/80
120/80
120/70
110/80
120/80
120/80
110/70
120/80
120/80
120/80
110/80
120/80
120/80
120/70
120/80
110/80
120/80
120/80
100/80
120/70
120/80
120/80
120/80
120/80
120/80
110/60
120/80
120/80
120/80
120/80
120/80
120/80
LATERAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
LATERAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
LATERAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
LATERAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
LATERAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
LATERAL
CENTRAL
CENTRAL
CENTRAL
120/80
110/70
120/80
120/80
120/80
110/80
120/80
120/80
120/70
120/80
110/80
120/80
120/80
100/80
120/70
120/80
120/80
120/80
120/80
120/80
110/60
120/80
120/80
120/80
120/80
120/80
120/80
120/80
100/60
120/80
120/80
120/80
120/80
120/80
110/80
120/80
120/70
110/80
120/80
120/80
110/70
120/80
120/80
120/80
110/80
120/80
120/80
120/70
120/80
110/80
120/80
120/80
100/80
120/70
120/80
120/80
120/80
120/80
120/80
110/60
120/80
120/80
120/80
120/80
120/80
140/90
120/80
100/60
120/80
120/80
110/70
120/80
120/80
120/80
110/80
120/80
120/80
120/70
120/80
110/80
120/80
120/80
100/80
120/70
120/80
120/80
120/80
120/80
120/80
110/60
120/80
120/80
120/80
120/80
120/80
120/80
150/90
100/60
120/80
120/80
120/80
120/80
120/80
110/80
120/70
110/80
120/80
120/80
110/70
120/80
120/80
120/80
110/80
120/80
120/80
120/70
120/80
110/80
120/80
120/80
100/80
120/70
120/80
120/80
120/80
120/80
120/80
110/60
120/80
120/80
120/80
120/80
120/80
120/80
140/90
100/60
120/80
120/80
140/90
120/80
110/70
120/80
120/80
120/80
110/80
120/80
120/80
120/70
150/100
110/80
120/80
120/80
100/80
150/100
120/80
120/80
120/80
120/80
120/80
110/60
120/80
120/80
120/80
120/80
120/80
170/100
120/80
100/60
120/80
120/80
120/80
120/80
120/80
120/70
110/80
120/80
120/80
110/70
120/80
120/80
120/80
110/80
120/80
150/100
120/70
120/80
110/80
120/80
120/80
100/80
120/70
150/100
120/80
120/80
150/100
120/80
110/60
120/80
120/80
140/90
120/80
120/80
120/80
150/100
100/60
120/80
120/80
PRE ECLAMPSIA
PRE ECLAMPSIA
PRE ECLAMPSIA
SEVERE
PREECLAMPSIA
PRE ECLAMPSIA
PRE ECLAMPSIA
PRE ECLAMPSIA
PRE ECLAMPSIA
ONSET AT 28
WEEKS
2ND TRIMESTER
S.NO. AGE PARITY BP PLACENTA
2ND
VISIT
BP
3RD
VISIT
BP
4TH VISIT
BP REMARKS
135.
136.
137.
138.
139.
140.
141.
142.
143.
144.
145.
146.
147.
148.
149.
150.
151.
152.
153.
154.
155.
156.
157.
158.
159.
160.
161.
162.
163.
164.
165.
166.
167.
168.
169.
170.
171.
172.
173.
174.
175.
176.
177.
178.
179.
180.
181.
182.
183.
184.
185.
186.
187.
188.
189.
190.
191.
192.
193.
194.
195.
196.
197.
198.
199.
200.
201.
202.
203.
22
28
24
18
23
29
20
21
18
24
30
24
18
25
29
21
18
23
28
19
24
19
25
27
19
24
34
26
26
17
23
27
24
19
22
28
17
21
29
35
21
22
17
20
30
24
19
21
29
36
24
23
18
22
34
28
18
23
27
28
18
24
18
25
31
18
31
23
24
PRIMI
G2P1L1
PRIMI
PRIMI
G2P1L0
G2P1L1
PRIMI
PRIMI
PRIMI
PRIMI
G2P1L1
G2P1L1
PRIMI
PRIMI
G2P1L0
G2P1L1
PRIMI
PRIMI
PRIMI
PRIMI
PRIMI
G2P1L1
PRIMI
PRIMI
PRIMI
PRIMI
PRIMI
G2P1L1
PRIMI
PRIMI
PRIMI
PRIMI
PRIMI
PRIMI
G2P1L1
PRIMI
PRIMI
PRIMI
PRIMI
G2P1L1
PRIMI
PRIMI
PRIMI
PRIMI
G2P1L1
PRIMI
PRIMI
PRIMI
G3P1L1A1
PRIMI
G2P1L1
PRIMI
PRIMI
G2P1L1
PRIMI
G2P1L1
PRIMI
PRIMI
G2P1L1
PRIMI
PRIMI
G3P2L2
PRIMI
PRIMI
PRIMI
PRIMI
G2P1L1
PRIMI
PRIMI
120/80
100/60
120/80
120/80
120/80
120/80
120/80
110/80
120/70
120/80
120/80
120/80
110/80
120/70
120/80
110/60
120/80
110/70
120/80
120/80
120/70
110/80
120/80
120/80
110/70
120/80
120/80
120/80
110/80
120/80
120/80
120/70
120/80
110/80
120/80
120/80
100/80
120/70
120/80
120/80
120/80
120/80
120/80
110/60
120/80
120/80
120/80
120/80
120/80
120/80
120/80
100/60
120/80
120/80
120/80
120/80
120/80
110/80
120/70
120/80
120/80
120/80
110/80
120/70
120/80
110/60
120/80
110/70
120/80
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
LATERAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
LATERAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
120/80
120/80
120/80
120/80
110/80
120/70
120/80
120/80
120/80
110/80
120/70
120/80
110/60
120/80
110/70
110/70
100/60
100/60
110/70
120/80
120/80
120/70
110/80
120/80
120/80
110/70
120/80
120/80
120/80
110/80
120/80
120/80
120/70
120/80
110/80
120/80
120/80
100/80
120/70
120/80
120/80
120/80
120/80
120/80
110/60
120/80
120/80
120/80
120/80
120/80
120/80
120/80
100/60
120/80
120/80
120/80
120/80
120/80
110/80
120/80
120/70
110/80
120/80
120/80
110/70
120/80
120/80
120/80
110/80
120/80
120/80
120/80
110/80
120/70
120/80
120/80
120/80
110/80
120/70
120/80
110/60
120/80
120/80
100/70
110/70
110/80
120/70
140/90
110/60
120/80
110/70
110/70
100/60
100/60
110/70
120/80
120/80
120/70
110/80
120/80
120/80
110/70
120/80
120/80
120/80
110/80
120/80
120/80
120/70
120/80
110/80
120/80
120/80
100/80
120/70
120/80
120/80
120/80
120/80
120/80
110/60
120/80
120/80
120/80
120/80
120/80
120/80
120/80
100/60
120/80
120/80
120/80
120/80
120/80
110/80
120/70
110/80
120/80
120/80
120/80
120/80
110/80
120/70
120/80
120/80
120/80
110/80
120/70
120/80
110/60
120/80
120/80
100/70
110/70
110/80
120/70
150/100
110/60
120/80
110/70
110/70
100/60
100/60
110/70
120/80
120/80
120/70
110/80
120/80
120/80
140/90
120/80
120/80
120/80
110/80
120/80
120/80
120/70
150/100
110/80
150/90
120/80
100/80
120/70
120/80
120/80
120/80
120/80
150/100
110/60
120/80
120/80
160/110
120/80
120/80
120/80
150/90
100/60
120/80
120/80
120/80
120/80
120/80
110/80
120/70
110/80
120/80
PRE ECLAMPSIA
PRE ECLAMPSIA
PRE ECLAMPSIA
PRE ECLAMPSIA
PRE ECLAMPSIA
ECLAMPSIA
2ND TRIMESTER
S.NO. AGE PARITY BP PLACENTA
2ND
VISIT
BP
3RD
VISIT
BP
4TH VISIT
BP REMARKS
204.
205.
206.
207.
208.
209.
210.
211.
212.
213.
214.
215.
216.
217.
218.
219.
220.
221.
222.
223.
224.
225.
226.
227.
228.
229.
230.
231.
19
23
26
18
22
27
21
22
17
21
28
24
32
21
21
16
20
29
23
23
21
18
21
30
33
29
22
19
PRIMI
PRIMI
G2P1L1
PRIMI
PRIMI
PRIMI
G2P1L1
PRIMI
PRIMI
PRIMI
G2P1L1
PRIMI
PRIMI
PRIMI
PRIMI
PRIMI
PRIMI
PRIMI
PRIMI
G3P1L1A1
PRIMI
PRIMI
G2P1L1
PRIMI
PRIMI
G3P2L2
PRIMI
PRIMI
120/80
120/70
110/80
120/80
120/80
110/70
120/80
120/80
120/80
110/80
120/80
120/80
120/70
120/80
110/80
120/80
120/80
100/80
120/70
120/80
120/80
120/80
120/80
120/80
110/60
120/80
120/80
120/80
CENTRAL
LATERAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
LATERAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
LATERAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
120/80
120/80
120/70
120/80
110/80
120/80
120/80
100/80
120/70
120/80
120/80
120/80
120/80
120/80
110/60
120/80
120/80
120/80
120/80
120/80
120/80
120/80
100/60
120/80
120/80
120/80
120/80
120/80
120/80
110/70
120/80
120/80
120/80
110/80
120/80
120/80
120/70
120/80
110/80
120/80
120/80
100/80
120/70
120/80
120/80
140/90
120/80
120/80
110/60
120/80
120/80
120/80
120/80
120/80
120/80
120/80
120/80
140/90
120/80
120/80
120/80
110/80
140/100
140/100
120/70
120/80
110/80
120/80
120/80
100/80
120/70
120/80
120/80
140/90
120/80
140/100
110/60
120/80
120/80
140/100
120/80
120/80
120/80
120/80
PRE ECLAMPSIA
PRE ECLAMPSIA
PRE ECLAMPSIA
PRE ECLAMPSIA
PRE ECLAMPSIA
PRE ECLAMPSIA
HIGH RISK PREGNANCY GROUP
2ND TRIMESTER
S.N0 AGE PARITY
BP PLACENTA
2ND VISIT
BP
3RD
VISIT
BP
4TH VISIT
BP HIGH RISK
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
18
28
23
24
34
23
21
24
21
18
29
23
24
36
24
18
30
24
23
29
19
28
24
23
19
27
23
40
19
26
23
19
19
27
28
24
19
29
19
30
23
38
24
18
29
23
16
28
23
24
18
26
23
24
32
24
23
PRIMI
G2P1L1
PRIMI
G3A2
PRIMI
PRIMI
PRIMI
PRIMI
PRIMI
PRIMI
G4P1L1A2
PRIMI
PRIMI
PRIMI
PRIMI
PRIMI
G2P1L1
PRIMI
PRIMI
PRIMI
PRIMI
G3A2
PRIMI
G3P1L1A1
PRIMI
PRIMI
PRIMI
PRIMI
PRIMI
G4A3
PRIMI
PRIMI
PRIMI
G3A2
G4A3
G4P1LOA2
PRIMI
PRIMI
PRIMI
G3P1L0A1
PRIMI
PRIMI
G4P1LOA2
PRIMI
G2P1L1
PRIMI
PRIMI
G4A3
PRIMI
G3A2
PRIMI
G3P1LOA1
PRIMI
PRIMI
PRIMI
PRIMI
PRIMI
120/80
110/70
120/80
120/80
120/70
110/80
120/80
120/80
110/70
120/80
120/80
120/80
110/80
120/80
120/80
120/70
120/80
110/80
120/80
120/80
100/80
120/70
120/80
120/80
120/80
120/80
120/80
110/60
120/80
120/80
120/80
120/80
120/80
120/80
120/80
100/60
120/80
120/80
120/80
120/80
120/80
110/80
120/70
120/80
120/80
120/80
110/80
120/70
120/80
110/60
120/80
110/70
120/80
120/80
120/70
110/80
120/80
CENTRAL
CENTRAL
LATERAL
LATERAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
LATERAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
LATERAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
LATERAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
LATERAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
LATERAL
LATERAL
CENTRAL
CENTRAL
CENTRAL
LATERAL
CENTRAL
CENTRAL
CENTRAL
120/80
110/70
110/70
100/60
100/60
110/70
120/80
120/80
120/70
110/80
120/80
120/80
110/70
120/80
120/80
120/80
110/80
120/80
120/80
120/70
120/80
110/80
120/80
120/80
100/80
120/70
120/80
120/80
120/80
120/80
120/80
110/60
120/80
120/80
120/80
120/80
120/80
120/80
120/80
100/60
120/80
120/80
120/80
120/80
120/80
110/80
120/70
120/80
120/80
120/80
110/80
120/70
120/80
110/60
120/80
110/70
110/70
120/70
110/80
120/80
120/80
110/70
120/80
120/80
120/80
110/80
120/80
120/80
120/70
120/80
110/80
120/80
120/80
100/80
120/70
120/80
120/80
120/80
120/80
120/80
110/60
120/80
120/80
120/80
120/80
120/80
120/80
120/80
100/60
120/80
120/80
120/80
120/80
120/80
110/80
120/70
120/80
120/80
120/80
110/80
120/70
120/80
110/60
120/80
120/80
100/70
110/70
110/80
120/70
120/80
110/60
120/80
110/70
110/70
120/80
120/80
150/100
150/90
120/80
140/90
120/70
120/80
110/80
120/80
120/80
100/80
140/90
150/100
120/80
120/80
120/80
120/80
110/60
120/80
120/80
120/80
120/80
140/100
120/80
120/80
100/60
120/80
120/80
120/80
150/100
120/80
110/80
120/70
120/80
120/80
120/80
150/90
120/70
120/80
150/90
170/110
110/70
120/80
120/80
140/100
110/80
120/80
140/90
140/90
120/80
120/80
120/80
140/100
120/80
120/80
120/70
GDM
BOH
GDM
BOH
GDM
GDM
GDM
GDM
BOH
GDM
INFERTILITY
BOH
GDM
BOH
BOH
BOH
GDM
BOH
INFERTILITY
GDM,BOH
BOH
BOH
GDM,BOH
GDM &
 INFERTILITY
2ND TRIMESTER
S.N0 AGE PARITY
BP PLACENTA
2ND VISIT
BP
3RD
VISIT
BP
4TH VISIT
BP HIGH RISK
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
24
24
27
17
23
22
22
24
21
22
24
24
PRIMI
PRIMI
PRIMI
G3A2
PRIMI
PRIMI
PRIMI
PRIMI
PRIMI
PRIMI
PRIMI
PRIMI
120/80
110/70
120/80
120/80
120/80
110/80
120/80
120/80
120/70
120/80
110/80
120/80
LATERAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
CENTRAL
100/60
100/60
110/70
120/80
120/80
120/70
110/80
120/80
120/80
110/70
120/80
120/80
100/60
100/60
110/70
120/80
120/80
120/70
110/80
120/80
120/80
110/70
120/80
120/80
150/100
110/80
120/80
120/80
110/70
120/80
120/80
120/70
110/80
120/80
120/80
110/70
GDM
BOH
GDM
